PatientsLikeMe announced today a five-year agreement with Genentech, a member of the Roche Group (SIX: RO, ROG; OTCQX: RHHBY), to explore use of PatientsLikeMe's global online patient network to develop innovative ways of researching patients' real-world experience with disease and treatment. The agreement is the first broad research collaboration between PatientsLikeMe and a pharmaceutical company and provides PatientsLikeMe the opportunity to expand its patient network in oncology.
"We envision a world where patient experience drives the way diseases are measured and medical advances are made. Genentech's leadership and commitment to this mission brings us closer to having patients at the true center of healthcare," said PatientsLikeMe Co-founder and Chairman Jamie Heywood. "With Genentech we can now embark on a journey to bring together many stakeholders across healthcare and collaborate with patients in a new way."
"At Genentech, we come to work every day with the goal of transforming patients' lives. The collaboration with PatientsLikeMe will allow us to learn more from patients with serious diseases, and better integrate their insights into our decision-making," said Bruce Cooper, M.D. senior vice president, Medical Affairs, Genentech. "We hope our participation will encourage broader engagement of others involved in the delivery of healthcare and support a stronger voice for patients."
The five-year agreement provides Genentech the opportunity to utilize PatientsLikeMe's Global Network Access, a new service for pharmaceutical companies that delivers a range of data, research and tools. The service includes:
Access to PatientsLikeMe's network to enable cross-sectional research and broader discovery of patient insights.
Enhanced customized research services and capabilities.
Focused research projects to evaluate and develop new medical evidence, measures and standards of health.
Access to PatientsLikeMe's clinical trial awareness tool, which allows patients to learn about clinical trials.